Jon CohenScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.The preliminary report one month ago that an experimental COVID-19 vaccine made by Pfizer and its partner BioNTech had 95% efficacy startled the world.
But few surprises occurred today when the vaccine advisory committee to the U.S. Food and Drug Administration (FDA) strongly backed the companies’ request for an emergency use authorization (EUA) of their candidate for people 16 years of age and older.
If the FDA promptly accepts the recommendation, as is expected in the next few days, select groups of people in the United States for the first time could being receiving a COVID-19 vaccine outside of a clinical trial.Other scientists.